# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Immunome (NASDAQ:IMNM) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(0.69) by...
JP Morgan analyst Brian Cheng initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Targ...
Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target...
- SEC Filing
- SEC Filing
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $27 t...
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 4...
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting so...